SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is capturing intense market attention as investors weigh its critical role in the AI infrastructure cycle against high expectations, leading to heavy options activity and polarized community debates over whether results are already priced in. Participants are closely monitoring the upcoming earnings for clarity on future demand, sector growth, and management guidance that could impact the broader market trajectory.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is experiencing significant volatility and downward pressure ahead of its upcoming earnings report, with community sentiment split between those viewing the price drop as a "bear trap" or value buying opportunity and others concerned about insider selling and tariff impacts. Investors remain deeply divided on the stock's future, as many weigh the potential for a growth rebound driven by successful brand acquisitions against the risks of sector rotation and institutional manipulation.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit shares are seeing extreme volatility following earnings that topped analyst estimates but provided cautious forward guidance. The community remains sharply divided, with some investors accumulating shares on the dip as a long-term AI-driven growth play, while others fear the firm's business model faces existential disruption from emerging AI automation tools.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors react to bullish CEO commentary regarding positive GPS immunotherapy data, which is being framed as superior to current standards of care. The community is heavily focused on the potential for an imminent short squeeze and clinical milestones, creating a volatile environment as traders monitor institutional buying activity and the upcoming oncology conference presentation.

Micware Co. Ltd. engages in software development services and innovative IT solutions mainly focused on the automotive and mobility sectors. It operates through the following segments: Software Defined Vehicles (SDV), Location-Based Services (LBS), and Others. The SDV segment relates to the development and sale of software systems designed for SDV, including IVI system software and other mobility-enhancing software products, conducted by its Japanese subsidiaries. The LBS segment covers the development and licensing of in-vehicle navigation software systems, and other geographic data-based services for business-to-business customers, mainly serving end users. The Other segment comprises software development services conducted by overseas subsidiaries designed for SDV, and business-to-consumer mobile app services unrelated to in-vehicle navigation. The company was founded by Kenji Narishima in March 2003 and is headquartered in Kobe, Japan.

Micware Co. Ltd. - ADR

Micware is experiencing extreme volatility and heavy retail attention as traders speculate on its potential for a massive rally following a recent IPO. The community is actively debating whether the stock is a legitimate opportunity or a classic pump-and-dump scheme, with many watching for breakout levels while navigating multiple trading halts.

Applied Digital Corporation

Applied Digital is currently trending following a major lease announcement with a high-grade hyperscaler that pushed its contracted AI capacity past the gigawatt threshold, fueling significant community excitement about its long-term growth. Investors are actively discussing the stock's potential for further gains as it continues to expand its data center footprint, with many using the recent price volatility as an opportunity to add to their positions.

AEVEX Corp. operates as a holding company. It operates through Tactical Systems and Global Solutions segments. The Tactical Systems segment focuses on design, development, and production of autonomous systems including unmanned aerial systems and unmanned surface vessels. The Global Solutions segment offers services and mission support to defense and intelligence customers. The company was founded in 2017 and is headquartered in Solana Beach, CA.

AEVEX Corp. - Ordinary Shares - Class A

AEVEX Corp

AEVEX Corp. is drawing significant community interest following its strong debut, fueled by its operational role in defense-tech and autonomous drone systems. Traders are actively debating the company's valuation and growth potential against established peers, with many focused on its substantial backlog and ability to secure key U.S. government contracts in an evolving defense environment.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending following news that the SEC has closed its three-year probe into the token, sparking a significant rally and community discussions regarding its potential to regain past highs. Traders are actively debating whether this movement represents a sustainable breakout or a temporary pump, while many enthusiasts highlight Zcash's privacy features and limited supply as catalysts for long-term growth.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is trending as investors debate the impact of advanced AI models like Anthropic's Mythos on cybersecurity software, with bullish sentiment focused on the stock's role in the new defensive infrastructure alongside Palo Alto Networks. While some community members worry about potential valuation compression and margin headwinds, others highlight the firm's critical platform expansion and persistent enterprise demand as institutional smart money continues to evaluate the sector's long-term resilience.

Syntec Optics Holdings, Inc. engages in the design and manufacture of optics and photonics enabled products. The company was founded in 1981 and is headquartered in Rochester, NY.

Syntec Optics Holdings Inc. - Ordinary Shares - Class A

Syntec Optics Holdings Inc

Syntec Optics (OPTX) is trending as investors react to its position as a domestic supplier of high-precision optics for defense, space, and AI infrastructure, further bolstered by recent defense purchase orders. The community is actively debating the company's growth potential against its financial positioning, with discussions focused on its role in the U.S. defense supply chain and its ability to scale production for LEO satellite and AR military programs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

US Reclassifies Weed: Can Cannabis ETFs Give Your Portfolio a New High? 

 Medical marijuana's US reclassification revives cannabis ETFs like WEED, with tax relief and reform hopes fueling sharp gains across the sector.

<ul class="summary-bullets"><li>Roth Capital upgraded its rating on TRLY to ‘Overweight,’ while Alliance Global maintained ‘neutral.’</li><li>Last year, the U.S. tightened rules on hemp-derived THC products, and now various states are also restricting or banning those products.</li><li>On Wednesday, Tirlay reported fiscal third-quarter results.</li></ul>Tilray Brands, Inc.’s third-quarter report drew a mixed reaction from Wall Street, as analysts balanced improving business fundamentals against looming regulatory shifts that could disrupt the marijuana industry.TLRY shares declined 1.5% in early premarket trading on Thursday, following a 5% dip the previous session.Alliance Global lowered its price target on TLRY to $7 from $9 (14% upside projection), while keeping a ‘Neutral’ rating, citing uncertainty over hemp restrictions.In November, the U.S. government tightened hemp regulations by capping&nbsp;total levels of tetrahydrocannabinol (THC) — the primary psychoactive component in cannabis that produces a “high”&nbsp;— at 0.3%, while also restricting products such as Delta-8, effectively curbing many intoxicating hemp items, including edibles, vapes, and beverages. Last month, Texas added further pressure by banning smokable hemp products and raising licensing fees, with more states expected to follow suit.On the other hand, Roth Capital upgraded its rating on TLRY to ‘Buy’ from ‘Neutral’ with an unchanged $10 price target.&nbsp; The research firm praised Tilray’s upbeat results, particularly the Canadian and international segments. Tilray shares are back at July 2025 levels, but the fundamental outlook has improved, and the potential for regulatory change is greater, the firm added.<h2 class="st-heading-2">Q3 Results Recap</h2>Revenue rose 19% to $206.7 million, helped by sharp growth in international sales, and came in higher than the $201.3 million expectation. Net loss narrowed significantly to $25.2 million from $793.5 million a year earlier. On an adjusted basis, loss per share of $0.24 missed the analyst target of $0.14.Tilray said international sales increased 73%, while its Tilray Pharma segment grew 34%. The company reaffirmed its outlook for fiscal 2026 core earnings of $62 million to $72 million.<h2 class="st-heading-2">Retail, Analyst View On TLRY</h2>On Stocktwits, retail sentiment for TLRY shifted from ‘bullish’ to ‘bearish’ following the results.&nbsp;“$TLRY Slow and steady wins the race. It sure ain't Nvidia, but I'll take it. Slight dip in margins, amid a sea of price compression. Revenue beat, and earnings meet. Not bad,”&nbsp;<a href="https://stocktwits.com/davidjbenz/message/649151732">said</a> a user.To be sure, traders are trading stock in anticipation of the U.S. potentially classifying marijuana as a Schedule III (S3) drug, indicating that it has a lesser potential for abuse and is allowed for use in specific medical treatment.Marijuana remains a Schedule I drug under federal law — the same category as heroin and LSD – a classification reserved for substances deemed to have high abuse potential and no accepted medical use. Weed stocks, including TLRY, rallied sharply in December after President Donald Trump announced&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-moves-a-step-closer-to-reclassifying-marijuana-as-a-less-dangerous-drug-a-breakout-moment-for-weed-industry/cLICa8WREFB">plans to reclassify</a>. It hasn’t happened yet.“Even without S3 record results, why are people so sad,”&nbsp;<a href="https://stocktwits.com/Tradefun1979/message/649157581">said</a> another Stocktwits user. “S3 is bonus but currently co. Is not doing bad, actually stellar results. I am buying and will hold Long term, very cheap now.”Meanwhile, Wall Street is in a wait-and-watch mode. Currently, seven out of 10 analysts have a ‘Hold’ rating on the stock, two rate it ‘Buy’, and one&nbsp;rates it ‘Strong Sell’, per Koyfin. Their average price target of $11.14 implies an over 80% upside from the stock’s last close.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

In this photo illustration, a Tilray Brands logo is seen displayed on a smartphone and in the background.

TLRY Stock Drops Premarket: Why Analysts Are Mixed Despite Upbeat Q3 Report 

Tirlay Brands shares have declined 33% year to date.

Equity

Tirlay Brands shares have declined 33% year to date.


Cannabis ETF (CNBS) Hits New 52-Week High

CNBS Cannabis ETF climbs to a 52-week high, fueled by rescheduling optimism and potential further gains.

<ul class="summary-bullets"><li>Tilray’s shares, as well as shares of other Cannabis producers, have been surging over the past few days.</li><li>This comes amid reports that President Trump is set to reclassify marijuana, which would result in cannabis companies falling under different tax regulations.</li><li>While awaiting the executive order, retail users on Stocktwits expressed optimism, noting that the TLRY stock could rally even further.</li></ul>Shares of Tilray Brands Inc. (TLRY) have soared nearly 72% over the past five trading sessions as investors await President Donald Trump’s executive order on marijuana reclassification.The New York City-headquartered pharmaceutical company produces and distributes cannabis for medicinal and adult use.Tilray’s shares, as well as shares of other Cannabis producers, have been surging over the past few days amid reports that President Trump is set to reclassify marijuana, which would result in cannabis companies falling under different tax regulations.<a href="https://stocktwits.com/symbol/TLRY">Tilray shares</a> were up nearly 5% in Wednesday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory, with the stock being the top trending ticker on the platform at the time of writing.<h2 class="st-heading-2">Retail’s Excited</h2>While awaiting the executive order, retail users on Stocktwits expressed optimism, noting that the TLRY stock could rally even further. One user expects Tilray’s shares to surge past $20 on Wednesday with ease.<stembedurl>https://stocktwits.com/LifeChangingProfits/message/639396013</stembedurl>Another user compared the reclassification of marijuana to a biotech company receiving fast-track approval from the U.S. Food and Drug Administration (FDA) for ten Phase 3 trials simultaneously.<stembedurl>https://stocktwits.com/Hoschton30548/message/639132205</stembedurl>One user expects the TLRY stock to surge past $50 by the end of the year.<stembedurl>https://stocktwits.com/Family2328/message/639372092</stembedurl><h2 class="st-heading-2">Other Cannabis Stocks Surge</h2>Apart from Tilray, expectations of marijuana reclassification have sent other cannabis stocks soaring, too.Canopy Growth Corp. (CGC), an Ontario-based company, saw its shares climb nearly 62% over the past five trading sessions. Aurora Cannabis Inc. (ACB) shares have climbed over 20%, while the Amplify Seymour Cannabis ETF (CNBS) has soared nearly 71% during this period.<h2 class="st-heading-2">Marijuana Reclassification</h2>According to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://abcnews.go.com/Politics/trump-sign-executive-order-reclassifying-marijuana-officials/story?id=128472615">report</a> by ABC News citing people familiar with the matter, President Trump is set to sign an executive order on Wednesday that would reclassify marijuana as a Schedule III drug.Under the current Drug Enforcement Administration guidelines, marijuana is listed as a Schedule I drug. The DEA defines Schedule III drugs as having “a moderate to low potential for physical and psychological dependence.”<a href="https://stocktwits.com/symbol/TLRY">TLRY stock</a> is up 5% year-to-date and 16% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ford-terminates-6-5-billion-battery-deal-lg-energy-after-retreating-from-evs/cLeOWmAREpD">Ford Terminates $6.5 Billion LG Energy Deal After Retreating From EVs — And Retail Is Split</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

TLRY Stock Gained Over 70% In 5 Days, Retail Optimism Spikes Ahead Of Trump's Marijuana Order

The New York City-headquartered pharmaceutical company produces and distributes cannabis for medicinal and adult use.

6 Top-Performing ETF Areas of Last Week 

Cannabis, metals, space and health care led ETF gains last week. WEED, CNBS, SIL, UFO, GDXJ, PLTM and OZEM outperformed despite tech weakness.

5 Best-Performing Leveraged ETFs of Last Week

Cannabis, space, nat gas & auto led last week's leveraged ETF winners. MSOX, RKLX, KOLD, VOYX and CVNX posted outsized gains despite tech weakness.

Cannabis ETFs Soar Double-Digits on Friday: Here's Why

Cannabis ETFs explode on reform buzz. CNBS, WEED, MSOS and MJ jumped double-digits on Dec. 12, 2025 as Trump reportedly weighs reclassifying marijuana, boosting optimism.

The Zacks Analyst Blog Highlights MSOS, CNBS, WEED, MJ and YOLO

Zacks Analyst Blog highlights MSOS, CNBS, WEED, MJ, and YOLO as marijuana ETFs soar over 100% in three months on U.S. legalization hopes and investor optimism.

From Loss to Lift-Off: Marijuana ETFs Rebound on Legalization Prospects 

Marijuana ETFs, such as WEED, MSOS, and CNBS, are rebounding as hopes for rescheduling boost investor optimism. 

Top-Performing ETF Areas of August That Are Up At Least 20% 

ETFs tied to Cannabis, Asia, China, materials and bitcoin miners led August's gains in Wall Street. ETFs like WEED, KSTR, CNXT, GBUG and WGMI won in August.

CNBS
Amplify Seymour Cannabis ETF

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest CNBS News

CNBSAmplify Seymour Cannabis ETF